A/Prof Liz Caldon

A/Prof Liz Caldon

Awards and Honours

2021-2024 Cancer Institute NSW Fellowship
2021-2023 Mavis Robertson NBCF Fellowship
2018 - The Ridley Ken Davies Award
2017 - Heliflite Young Explorer Award
2017-2020 National Breast Cancer Foundation Career Development Fellowship
2015 - CHAMP Private Equity Young Pioneer Award
2014 - Cancer Institute Career Development Fellowship
2013 - Cure Cancer Conference and Professional Development Grant
2013 - “Best Translational Research Presentation”, Lowy Cancer Symposium, UNSW, Sydney, Australia
2011-2016 - National Breast Cancer Foundation Postdoctoral Fellowship
2011 - Cure Cancer Australia Postdoctoral Fellowship
2010 - Young Garvan Fellowship
2009 - Qantas Research Travel Award
2005-2007 - Cancer Institute NSW Scholar
2004 - Beth Yarrow Scholarship
2003 - LH Ainsworth Scholarship in Cancer Research
2002 - Connaught Graduate Fellowship, University of Toronto


2007 - PhD, University of NSW, Sydney - Australia
2003 - MSc University of Toronto - Canada
2001 - Bachelor of Laws (LLB), University of New South Wales, Sydney - Australia
1998 - BSc (Hons, University Medal) University of New South Wales, Sydney - Australia


The amazing organisations that make our research possible are:

  • NBCF (IIRS Grants)
  • Cancer Institute NSW
  • NHMRC (Project Grant)
  • Sphere CAG
  • Tour de Cure
  • Perpetual Impact
  • Mostyn Foundation

Selected Publications


  1. Hickey, Theresa E., Luke A. Selth, Kee Ming Chia, Geraldine Laven-Law, Heloisa H. Milioli, Daniel Roden, Shalini Jindal, Mun Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen N. Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C. Elizabeth Caldon, Tarek M. Abdel-Fatah, Ian O. Ellis, Wilbert Zwart, Carlo Palmieri, Carol A. Sartorius, Alex Swarbrick, Elgene Lim, Jason S. Carroll, and Wayne D. Tilley. 2021. 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27: 310-20.
  2. C Lee, K Fernandez, S Alexandrou, CM Sergio, N Deng, S Rogers, A Burgess, CE Caldon (2020) “Cyclin E2 promotes whole genome doubling in breast cancer” Cancers accepted
  3. A Burgess*, CE Caldon* (2020) “Proceedings from ACCM19: Cell Cycle, DNA Damage Response and Telomeres” Frontiers in Cell and Developmental Biology accepted *co-senior
  4. N Portman, HH Milioli, S Alexandrou, R Coulson, A Yong, KJ Fernandez, KM Chia, E Halilovic, D Segara, A Parker, S Haupt, Y Haupt, W Tilley, A Swarbrick, CE Caldon*, E Lim* (2020) “MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer” Breast Cancer Research accepted *co-senior
  5. CE Caldon (2020) “Friends and foes: our evolving understanding of the link between Fbxw7 and p53 in cancer” Neoplasia accepted
  6. HH Milioli, S Alexandrou, E Lim, CE Caldon (2020)“Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets” Endocrine-Related Cancer 27 (5), R93-R112
  7. J Achinger-Kawecka, F Valdes Mora, P Luu, K Giles, CE Caldon, W Qu, S Nair, S Soto, W Locke, N Yeo-Teh, C Gould, Q Du, G Smith, I Ramos, K Fernandez, D Hoon, J Gee, C Stirzaker and S Clark (2020) “Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer” Nature Communications 11 (1), 1-17
  8. S Tadesse, A Anshabo, N Portman, E Lim, W Tilley, CE Caldon* and S Wang* (2020) “Targeting CDK2 in cancer: challenges and opportunities for therapy” Drug Discovery Today 25 (2), 406-413 *Co-senior
  9. CE Caldon, A Burgess (2019) “Label Free, Quantitative Single-Cell Fate Tracking of Time-Lapse Movies” MethodsX, 6, 2468-2475
  10. L Castillo, A Young, A Mawson, P Schafranek, A M Steinmann, D Nessem, A Parkin, A Johns, Angela Chou, A MK Law, MC Lucas, KJ Murphy, N Deng, D Gallego-Ortega, CE Caldon, Australian Pancreatic Cancer Genome Initiative (APGI), P Timpson, M Pajic, CJ Ormandy and SR Oakes (2019) “MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma” Oncogene 39 (8), 1821-1829
  11. Q Du*, SA Bert*, NJ Armstrong, CE Caldon, J Song, S Nair, CM Gould, P Loi Luu, T Peters, A Khoury, W Qu, E Zotenko, C Stirzaker, SJ Clark (2019) “DNA replication timing in concert with epigenome remodelling is associated with the nature of chromosomal rearrangements in cancer “ Nature Communications 10 (1), 1-15 *Equal contribution
  12. N Currey*, Z Jahan*, CE Caldon, P N Tran, F Benthani, P De Lacavalerie, DL Roden, BS Gloss, C Campos, EG Bean, A Bullman, S Reibe-Pal, ME Dinger, MA Febbraio, SJ Clarke, JC Howard, JE Dahlstrom, MRJ Kohonen-Corish (2019)” Mouse model of ‘Mutated in Colorectal Cancer’ gene deletion reveals novel pathways in colitis and cancer” Cellular and Molecular Gastroenterology and Hepatology 7 (4), 819-839 *Equal contribution
  13. Tadesse S, CE Caldon, W Tilley and S Wang (2019) "Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update" Journal of Medicinal Chemistry 62 (9), 4233-4251
  14. Chia K, Milioli H, Portman, N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley W, Hickey T, & Lim E (2019) “Non-canonical AR activity facilitates endocrine resistance in breast cancer”, Endocrine-Related Cancer, 26(2), 251-264
  15. Portman, N, Alexandrou, S, Carr, E, Wang, S, Lim, E, CE Caldon (2019) “Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer” Endocrine Related Cancer 26 (1), R15-R30
  16. Alexandrou, S., George, S.M., Ormandy, C.J., Lim, E., Oakes, S.R., Caldon, C.E. (2019) The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences 20: 667.
  18. Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP*, Timpson P*. (2018) “Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer”. Cell Reports 23(11):3312-26. *Co-senior
  19. Rogers, S., R. A. McCloy, B. L. Parker, D. Gallego-Ortega, A. M. K. Law, V. T. Chin, J. R. W. Conway, D. Fey, E. K. A. Millar, S. O’Toole, N. Deng, A. Swarbrick, P. D. Chastain, A. J. Cesare, P. Timpson, E. Caldon, D. R. Croucher, D. E. James, D. N. Watkins and A. Burgess (2018). "MASTL overexpression promotes chromosome instability and metastasis in breast cancer." Oncogene 37:4518–4533.
  20. Aziz, D., D. Etemadmoghadam,* E. Caldon,* G. Au-Yeung, N. Deng, R. Hutchinson, D. Bowtell, P. Waring and A. O. C. S. Group (2018). "19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes." Gynecologic Oncology. 151 (2), 327-336 *Equal contribution
  21. Law, A. M. K., J. X. M. Yin, L. Castillo, A. I. J. Young, C. Piggin, S. Rogers, C. E. Caldon, A. Burgess, E. K. A. Millar, S. A. O’Toole, D. Gallego-Ortega, C. J. Ormandy and S. R. Oakes (2017). "Andy’s Algorithms: new automated digital image analysis pipelines for FIJI." Scientific Reports 7(1): 15717.
  22. Caldon, C.E. (2016) Cdk2 regulates metastasis suppressor Cell Cycle, i15(6): 779-780
  23. Rogers, D. Fey, R.A. McCloy, B.L. Parker, N.J. Mitchell, R.J. Payne, R.J. Daly, D.E. James, C.E. Caldon, D.N. Watkins, D.R. Croucher, and A. Burgess (2016) “PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells” Journal of Cell Science 129(7) 1340-1354.
  24. Susanto, J.M., E.K. Colvin, M. Pinese, D.K. Chang, M. Pajic, A. Mawson, E. Caldon, E.A. Musgrove, S.M. Henshall, R.L. Sutherland A.V. Biankin, C.J. Scarlett (2015) “The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2'deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivoInternational Journal of Oncology 46 (5), 2223-2230.
  25. Rogers, S., B.S. Gloss, C.S. Lee, C.M. Sergio, M.E. Dinger, E.A. Musgrove, A. Burgess, E. Caldon. (2015) “Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cellsCell Division 10 (1), 1.
  26. Loh, S.W., Cooper, C., Selinger, C.I., Barnes, E., Chan, C., Carmalt, H., West, R., Gluch, L., Beith, J.M., Caldon, C.E., O'Toole, S. (2015) “Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast.” Journal of Clinical Pathology jclinpath-2014-202331.
  27. Caldon, C.E. (2014) “Estrogen signalling and the DNA damage response in hormone dependent breast cancers.” Frontiers in Oncology 4:106.
  28. McCloy R.A., S. Rogers, E. Caldon, T. Lorca, A. Castro, A. Burgess. (2014) “Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events” Cell Cycle 13 (9), 0-1.
  29. Stone, M.J. Cowley, F. Valdes-Mora, R.A. McCloy, C.M. Sergio, D. Gallego-Ortega, C.E. Caldon, C.J. Ormandy, A.V. Biankin, J.M. Gee, R.I. Nicholson, C.G. Print, S.J. Clark, E.A. Musgrove. (2013) “BCL-2 hypermethylation is a potential biomarker of sensitivity to anti-mitotic chemotherapy in endocrine-resistant breast cancer.” Molecular Cancer Therapeutics 12 (9), 1874-1885
  30. Caldon C.E., C.M. Sergio, A. Burgess, A.J. Deans, R.L. Sutherland, E.A. Musgrove. (2013) “Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1” Cell Cycle 12(4):606-17.

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.

  1. Caldon C.E.*, C.M. Sergio, R.L. Sutherland, E.A. Musgrove. (2013) “Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells” Cell Cycle 12(4):596-605. *Corresponding author

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.­­

  1. Kalyuga M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, C.J. Ormandy. (2012) “ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.” PLoS Biology 10(12):e1001461.
  2. Ortiz-Padilla, C., D. Gallego-Ortega, B. C. Browne, F. Hochgrafe, E. Caldon, R. J. Lyons, D. R. Croucher, D. Rickwood, C. J. Ormandy, T. Brummer and R. J. Daly (2012). "Functional characterization of cancer-associated Gab1 mutations." Oncogene 32 (21), 2696-2702
  3. Caldon C.E., C. M. Sergio, J. Kang, A. Muthukaruppan, M. N. Boersma, A. Stone, J. Barraclough, C. S. Lee, M. A. Black, L. D. Miller, J. M. Gee, R. I. Nicholson, R. L. Sutherland, C. G. Print and E. A. Musgrove (2012). "Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells." Molecular Cancer Therapeutics 11(7): 1488-1499.
  4. Musgrove, E. A., E. Caldon, J. Barraclough, A. Stone and R. L. Sutherland (2011). "Cyclin D as a therapeutic target in cancer." Nature Reviews Cancer 11(8): 558-572.
  5. Hilton, H.N., M. Kalyuga, M.J. Cowley, M.C. Alles, H.J. Lee, E. Caldon, K. Blazek, W. Kaplan, E.A. Musgrove, R.J. Daly, M.J. Naylor, J.D. Graham, C.L. Clarke and C.J. Ormandy (2010). "The anti-proliferative effects of progestins in T47D breast cancer cells are tempered by induction of the ETS transcription factor Elf5." Molecular Endocrinology 24(7), 1380-92.
  6. Caldon C.E., R. L. Sutherland and E. A. Musgrove (2010). "Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer." Cell Cycle 9: 10.
  7. Caldon C.E. and E. A. Musgrove (2010). "Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer." Cell Division 5(2).
  8. Caldon C.E., C. M. Sergio, J. Schutte, M. N. Boersma, R. L. Sutherland, J. S. Carroll and E. A. Musgrove (2009). "Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc." Molecular and Cellular Biology 29(17): 4623-4639.
  9. Musgrove, E.A., C.M. Sergio, S. Loi, C.K. Inman, L.R. Anderson, M.C. Alles, M. Pinese, E. Caldon, J. Schutte, M. Gardiner-Garden, C.J. Ormandy, G. McArthur, A.J. Butt and R.L. Sutherland (2008). "Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer." PLoS ONE 3(8): e2987.
  10. Caldon C.E., A. Swarbrick, C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini." Cancer Research 68(8): 3026-3036.
  11. Caldon C.E., C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation." Oncogene 27(1): 126-138.
  12. Butt, A.J., E. Caldon, C. M. McNeil, A. Swarbrick, E. A. Musgrove and R. L. Sutherland (2008). "Cell cycle machinery: links with genesis and treatment of breast cancer." Advances in Experimental Medicine and Biology 630: 189-205.
  13. Caldon C.E., R. J. Daly, R. L. Sutherland and E. A. Musgrove (2006). "Cell cycle control in breast cancer cells." Journal of Cellular Biochemistry 97(2): 261-274.
  14. Brummer, T., D. Schramek, V. M. Hayes, H. L. Bennett, E. Caldon, E. A. Musgrove and R. J. Daly (2006). "Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein." Journal of Biological Chemistry 281(1): 626-637.
  15. Swarbrick, A., M.C. Akerfeldt, C.S. Lee, C.M. Sergio, E. Caldon, L.J. Hunter, R.L. Sutherland and E.A. Musgrove (2005)"Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1." Oncogene 24(3): 381-9.
  16. Nadkarni, M. A., E. Caldon, K. L. Chhour, I. P. Fisher, F. E. Martin, N. A. Jacques and N. Hunter (2004). "Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria." Journal of Clinical Microbiology 42(11): 5238-5244.
  17. Kus, B. M., E. Caldon, R. Andorn-Broza and A. M. Edwards (2004). "Functional interaction of 13 yeast SCF complexes with a set of yeast E2 enzymes in vitro." Proteins 54(3): 455-467.
  18. Paramaesvaran, M., K. A. Nguyen, Caldon, J. A. McDonald, S. Najdi, G. Gonzaga, D. B. Langley, A. DeCarlo, M. J. Crossley, N. Hunter and C. A. Collyer (2003). "Porphyrin-mediated cell surface heme capture from hemoglobin by Porphyromonas gingivalis." Journal of Bacteriology 185(8): 2528-2537.
  19. Caldon C.E. and P. E. March (2003). "Function of the universally conserved bacterial GTPases." Current Opinion in Microbiology 6(2): 135-139.
  20. Caldon C.E., P. Yoong and P. E. March (2001). "Evolution of a molecular switch: universal bacterial GTPases regulate ribosome function." Molecular Microbiology 41(2): 289-97.